🔗 Share this article

A senior medical figure was removed from involvement in a significant medical study concerning hormone suppressants subsequent to allegations of bias came to light.

Reported Intervention Led to Trial Halt

As reported by media coverage, Professor Jacob George, the chief scientific advisor at the regulatory agency, raised issues which led to the pausing of a government-funded Pathways trial during early 2024.

The agency announced recently that George was recusing him of involvement in the study once questioning online comments made previously were identified.

Nature of Online Posts

In a post, George described author J.K. Rowling as a “treasure of our time.” Separately, the professor stated that “the denial of fundamental biological fact was worrisome” regarding questions about a elite boxer’s sex.

The regulator clarified that although the comments were posted prior to his role began, he had been recused of involvement in the trial as a abundance of caution.

Particulars Regarding the Halted Pathways Study

The research project, that was intended to evaluate the impact of hormone suppressants on children questioning their gender, was set to commence signing up participants during January.

But, it was suspended in the following month when the agency voiced apprehensions regarding the safety of adolescents involved.

• The most junior subjects were projected to be 10 to 11 among girls while eleven to twelve among assigned male at birth.
• The study organizers stated earlier that the rigorous selection process meant participants would almost certainly be older.
• But, officials have since said the lowest age requirement should be 14 owing to an uncertain potential” for lasting health consequences.”

This clinical trial had planned to include an estimated 226 adolescents during the following several years.

Background Following the Independent Report

This study was commissioned subsequent to a recommendation by a major report on children’s gender care, which found that the quality of the studies claiming to demonstrate the benefits of this type of treatment for children experiencing gender dysphoria were weak.”

Doctor Hilary Cass, who chaired the report, once stated her findings exposed a notably limited evidence base” for the usefulness of such treatments.

She noted, considering that there exist clinicians, children and parents that believe deeply in the positive outcomes, a study remained the sole method ahead to make sense of this.”

Expert Criticism Regarding the Decision

Doctor Max Davie, a child health specialist, said there existed no strong scientific reason to pause the trial.

“The social media posts from Prof George offer a clear indication of his individual stance on the topic,” Dr. Davie stated. “The professor is quite at liberty to possess whatever views about this subject he wishes, however what is unacceptable would be to let these opinions to affect the performance of his official role.”

The doctor concluded: “For clarity, there is no persuasive medical basis to stop this study. Although Prof George’s personal convictions are not the sole possible explanation for the regulator’s abrupt change of position, they are the only one where we possess evidence.”

Agency Response and Next Steps

An regulatory spokesperson said: “In all clinical trials, our foremost duty remains the safety as well as welfare of the trial participants. In line with that commitment, complex studies are kept continuously being monitored and the agency maintains an active conversation with trial sponsors.”

“The MHRA have expert scientific, medical and oversight specialists who function in a collaborative group to provide research-informed decisions on clinical trials. This team will continue to meet alongside the research team to work through the subsequent actions productively.”

“Subsequent to the finding regarding social media activity made before his tenure began, Prof Jacob George is recused of continued participation with the Pathways clinical trial as a precaution.”